Use of Antipsychotic Drugs During Pregnancy
- 10 Downloads
Purpose of review
Antipsychotics are frequently prescribed to women of childbearing age and are increasingly prescribed during pregnancy. A small, but growing, body of research on implications for pregnancy and infant outcomes is available to inform the risks and benefits of in utero exposure to antipsychotics. This review examines the existing published research on the use of common typical and atypical antipsychotics in pregnancy and the implications for pregnancy and infant outcomes.
The majority of studies do not show associations with major malformations and antipsychotic use in pregnancy, with the possible exception of risperidone. There is concern that atypical antipsychotics may be associated with gestational diabetes. Metabolic changes during pregnancy may necessitate dose adjustments.
In general, it is recommended that women who need to take an antipsychotic during pregnancy continue the antipsychotic that has been most effective for symptom remission. Further study on risperidone is needed to better understand its association with malformations, and it is not considered a first-line agent for use during pregnancy.
KeywordsAntipsychotic Neuroleptic Pregnancy Lactation Breastfeeding
Compliance with Ethical Standards
Conflict of Interest
Dr. Clark reports grants from NICHD-K23 grant, during the conduct of the study, and Miller Medical Communications as a speaker for CME activities on postpartum depression.
Hannah K. Betcher and Catalina Montiel declare that they have no conflict of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
References and Recommended Reading
Papers of particular interest, published recently, have been highlighted as: • Of importance
- 4.Toh S, Li Q, Cheetham TC, Cooper WO, Davis RL, Dublin S, et al. Prevalence and trends in the use of antipsychotic medications during pregnancy in the U.S., 2001-2007: a population-based study of 585,615 deliveries. Arch Womens Ment Health. 2013;16(2):149–57. https://doi.org/10.1007/s00737-013-0330-6.CrossRefPubMedPubMedCentralGoogle Scholar
- 12.Alder J, Fink N, Bitzer J, Hosli I, Holzgreve W. Depression and anxiety during pregnancy: a risk factor for obstetric, fetal and neonatal outcome? A critical review of the literature. J Matern Fetal Neonatal Med. 2007;20(3):189–209. https://doi.org/10.1080/14767050701209560.CrossRefPubMedGoogle Scholar
- 16.Cantwell R, Clutton-Brock T, Cooper G, Dawson A, Drife J, Garrod D et al. Saving mothers’ lives: reviewing maternal deaths to make motherhood safer: 2006–2008. The Eighth Report of the Confidential Enquiries into Maternal Deaths in the United Kingdom. BJOG : an international journal of obstetrics and gynaecology. 2011;118 Suppl 1:1–203. doi: https://doi.org/10.1111/j.1471-0528.2010.02847.x.
- 17.Centers for Disease C, Prevention. Update on overall prevalence of major birth defects—Atlanta, Georgia, 1978–2005. MMWR Morb Mortal Wkly Rep. 2008;57(1):1–5.Google Scholar
- 18.Bajaj L, Hambidge S, Nyquist A, Kerby G. Berman’s pediatric decision making. 5th ed. Elsevier; 2011.Google Scholar
- 19.Centers for Disease Control and Prevention. World Birth Defects Day. 2018. https://www.cdc.gov/features/birth-defects-day/. Accessed 10/18/18 2018.
- 20.FDA. Pregnancy and Lactation Labeling Final Rule. 2014. https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/Labeling/ucm093307.htm. Accessed 5/29/15 2015.
- 21.• Huybrechts KF, Hernandez-Diaz S, Patorno E, Desai RJ, Mogun H, Dejene SZ, et al. Antipsychotic use in pregnancy and the risk for congenital malformations. JAMA psychiatry. 2016;73(9):938–46. https://doi.org/10.1001/jamapsychiatry.2016.1520 Largest study to date examining the risk of congenital malformations after antipsychotic expsoure. CrossRefPubMedPubMedCentralGoogle Scholar
- 23.Petersen I, Sammon CJ, McCrea RL, Osborn DPJ, Evans SJ, Cowen PJ, et al. Risks associated with antipsychotic treatment in pregnancy: comparative cohort studies based on electronic health records. Schizophr Res. 2016;176(2–3):349–56. https://doi.org/10.1016/j.schres.2016.07.023.CrossRefPubMedGoogle Scholar
- 25.Dieulangard P. Sur un cas d’ectro-phocomelie peutetre d'origine medicamenteuse. Gynecol Obstet. 1966;18:85–7.Google Scholar
- 26.Briggs G, Freeman R, Jaffe S. Drugs in pregnancy and lactation 9th edition. 9th ed.: Lippincott Williams & Wilkins; 2011.Google Scholar
- 32.Heinonen O, Sloan D, Shapiro S. Birth defects and drugs in pregnancy. Littleton, Massachusetts: Publishing Sciences Group Inc; 1977.Google Scholar
- 33.• Cohen LS, Viguera AC, McInerney KA, Freeman MP, Sosinsky AZ, Moustafa D, Marfurt SP et al. Reproductive Safety of Second-Generation Antipsychotics: Current Data From the Massachusetts General Hospital National Pregnancy Registry for Atypical Antipsychotics. Am J Psychiatry 2016;173(3):263–70. https://doi.org/10.1176/appi.ajp.2015.15040506. Comprehensive evaluation of quetiapine expsoure in pregnancy.
- 35.Sadowski A, Todorow M, Yazdani Brojeni P, Koren G, Nulman I. Pregnancy outcomes following maternal exposure to second-generation antipsychotics given with other psychotropic drugs: a cohort study. BMJ Open. 2013, 3(7). https://doi.org/10.1136/bmjopen-2013-003062.
- 37.• Bellet F, Beyens MN, Bernard N, Beghin D, Elefant E, Vial T. Exposure to aripiprazole during embryogenesis: a prospective multicenter cohort study. Pharmacoepidemiol Drug Saf. 2015;24(4):368–80. https://doi.org/10.1002/pds.3749 Study of the use of aripiprazole in pregnancy and pregnancy and birth related outcomes. CrossRefPubMedGoogle Scholar
- 38.Montastruc F, Salvo F, Arnaud M, Begaud B, Pariente A. Signal of gastrointestinal congenital malformations with antipsychotics after minimising competition bias: a disproportionality analysis using data from Vigibase((R)). Drug Saf. 2016;39(7):689–96. https://doi.org/10.1007/s40264-016-0413-1.CrossRefPubMedGoogle Scholar
- 39.• Galbally M, Frayne J, Watson SJ, Snellen M. Aripiprazole and pregnancy: a retrospective, multicentre study. J Affect Disord. 2018;238:593–6. https://doi.org/10.1016/j.jad.2018.06.004 Study of the use of aripiprazole in pregnancy and pregnancy and birth related outcomes.CrossRefPubMedGoogle Scholar
- 47.Boden R, Lundgren M, Brandt L, Reutfors J, Kieler H. Antipsychotics during pregnancy: relation to fetal and maternal metabolic effects. Arch Gen Psychiatry. 2012;69(7):715–21. https://doi.org/10.1001/archgenpsychiatry.2011.1870.CrossRefPubMedGoogle Scholar
- 53.Dev V, Krupp P. Adverse event profile and safety of clozapine. Rev Contem Pharmacoth. 1995;6:197–208.Google Scholar
- 63.Johnson KC, LaPrairie JL, Brennan PA, Stowe ZN, Newport DJ. Prenatal antipsychotic exposure and neuromotor performance during infancy. Arch Gen Psychiatry. 2012;69(8):787–94. https://doi.org/10.1001/archgenpsychiatry.2012.160.CrossRefPubMedPubMedCentralGoogle Scholar
- 65.Hurault-Delarue C, Damase-Michel C, Finotto L, Guitard C, Vayssiere C, Montastruc JL, et al. Psychomotor developmental effects of prenatal exposure to psychotropic drugs: a study in EFEMERIS database. Fundam Clin Pharmacol. 2016;30(5):476–82. https://doi.org/10.1111/fcp.12209.CrossRefPubMedGoogle Scholar
- 68.• Hatters Friedman S, Moller-Olsen C, Prakash C, North A. Atypical antipsychotic use and outcomes in an urban maternal mental health service. Int J Psychiatry Med. 2016;51(6):521–33. https://doi.org/10.1177/0091217417696739 Evaluation of atypical antipsychotic use and pregnancy and birth outcomes. CrossRefPubMedGoogle Scholar
- 69.• Park Y, Hernandez-Diaz S, Bateman BT, Cohen JM, Desai RJ, Patorno E, et al. Continuation of atypical antipsychotic medication during early pregnancy and the risk of gestational diabetes. Am J Psychiatry. 2018;175(6):564–74. https://doi.org/10.1176/appi.ajp.2018.17040393 Evaluation of atypical antipsychotic use and gestational diabetes. CrossRefPubMedGoogle Scholar
- 73.Paulzen M, Goecke TW, Kuzin M, Augustin M, Grunder G, Schoretsanitis G. Pregnancy exposure to quetiapine—therapeutic drug monitoring in maternal blood, amniotic fluid and cord blood and obstetrical outcomes. Schizophr Res. 2018;195:252–7. https://doi.org/10.1016/j.schres.2017.09.043.CrossRefPubMedGoogle Scholar
- 75.Risperidone. Drugs and Lactation Database (LactMed). Bethesda (MD)2006.Google Scholar
- 76.Lurasidone. Drugs and Lactation Database (LactMed). Bethesda (MD)2006.Google Scholar
- 77.McAllister-Williams RH, Baldwin DS, Cantwell R, Easter A, Gilvarry E, Glover V, et al. British association for psychopharmacology consensus guidance on the use of psychotropic medication preconception, in pregnancy and postpartum 2017. J Psychopharmacol. 2017;31(5):519–52. https://doi.org/10.1177/0269881117699361.CrossRefPubMedGoogle Scholar
- 79.Hasan A, Falkai P, Wobrock T, Lieberman J, Glenthoj B, Gattaz WF, et al. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia. Part 3: Update 2015 Management of special circumstances: Depression, Suicidality, substance use disorders and pregnancy and lactation. World J Biol Psychiatry. 2015;16(3):142–70. https://doi.org/10.3109/15622975.2015.1009163.CrossRefPubMedGoogle Scholar